Start Ups

Birgitte Kornum (IN), Petrine Wellendorph (ILF) and Bente Frølund (ILF) have Aug. 20, 2018 founded the biotech company Ceremedy ApS together with Casper Tind Hansen (BiOrigin) with a pre-seed grant from the Novo Nordisk Foundation. The aim of the company is to perform drug discovery in CNS disorders based on analogues of the neuroactive substance gamma-hydroxybutyric acid (GHB).

Mitii Development A/S was established in 2009 with the purpose to develop and commercialize internet based training systems from perception, cognition and motor control. Mitii Development A/S has developed a unique training method for people with different types of brain damage. Our Prof. Jens Bo Nielsen (IN) contributed to the development of the concept. Mitii Development is owned by the Elsass Foundation.

RetiPharma is developing products for treatment of degenerative eye disorders in parallel with building a unique translational in vivo platform. The company was founded in 2018 based on neuroprotective research conducted by Associate Prof. David Woldbye, IN and Assistant Prof. Andreas Sørensen and scientists from the University Hospital, Rigshospitalet. The establishment was made possible with a pre-seed grant from the Novo Nordisk Foundation and Bio Innovation Institute (IN).

Combigene’s scientific founders, Associate Prof. David Woldbye, Department of Neuroscience, UCPH, and Prof. Merab Kokaia, Lund University were among the first in the world to demonstrate that a neuropeptide in the brain, NPY (neuropeptide Y), suppresses epileptic seizures in animals and that the effect could be further strengthened with the addition of the Y2 NPY receptor. On 25th May 2015 CombiGene was listed on SPOTLIGHT Stock Market.Since the original discovery, CombiGene has successively built up a unique body of knowledge concerning gene therapy mechanisms in relation to various neurological illnesses, with an initial focus on epilepsy. Recently, the company was listed at Nasdaq First North stock market.

Panion Animal Heath AB was founded in July 2015 as a wholly owned subsidiary of CombiGene AB and with the purpose to develop and commercialize the canine (dog) application of CombiGene AB’s technology for gene therapeutic treatment of drug refractory epilepsy. The scientific foundation goes back almost 20 years to the researchers Associate Prof. David Woldbye, Department of Neuroscience, UCPH and Prof. Merab Kokaia, Lund University, and was based on the hypothesis that neuropeptide Y (NPY) is part of the body’s own defense mechanism for preventing epileptic seizures. They discovered that a pronounced anti-seizure effect could be achieved if an increased level of NPY is combined with an increased level of the receptor Y2 in the brain.